🏛️ Verified NIH Record • Updated 2026-07-27
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments (NCT04058756)
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Novartis Pharmaceuticals
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to continue to assess safety and tolerability, and to allow continued access to study treatment for subjects already receiving spartalizumab as single agent or in combination with other study treatments.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (2 items) and avoid the listed exclusions (3 items).
Location: Columbia University Medical Center — New York, New York
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Subject has been permanently discontinued from spartalizumab in the parent protocol for any reason other than enrollment in the Roll over Study
- Subject does not meet the criteria specified in the parent protocol criteria for continued study treatment.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (48 Sites)
- Columbia University Medical Center — New York, New York
- Providence Portland Medical Center — Portland, Oregon
- MD Anderson Cancer Center Uni of Te — Houston, Texas
- Novartis Investigative Site — Leuven,
- Novartis Investigative Site — Liège,
- Novartis Investigative Site — Toronto, Ontario
- Novartis Investigative Site — Montreal, Quebec
- Novartis Investigative Site — Guangzhou, Guangdong
- Novartis Investigative Site — Guangzhou,
- Novartis Investigative Site — Brno,
- Novartis Investigative Site — Lille,
- Novartis Investigative Site — Lyon,
- Novartis Investigative Site — Marseille,
- Novartis Investigative Site — Marseille,
- Novartis Investigative Site — Villejuif,
- Novartis Investigative Site — Jena, Thuringia
- Novartis Investigative Site — Essen,
- Novartis Investigative Site — Heidelberg,
- Novartis Investigative Site — Ulm,
- Novartis Investigative Site — Hong Kong, Hong Kong
- Novartis Investigative Site — High West,
- Novartis Investigative Site — Hong Kong,
- Novartis Investigative Site — Debrecen, Hajdu Bihar Megye
- Novartis Investigative Site — Budapest,
- Novartis Investigative Site — Milan, MI
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.